LeMaitre Vascular, Inc. (LMAT): Price and Financial Metrics


LeMaitre Vascular, Inc. (LMAT)

Today's Latest Price: $38.88 USD

1.13 (2.99%)

Updated Nov 23 6:55pm

Add LMAT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

LMAT Stock Summary

  • LMAT's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,616.42 -- higher than 97.52% of US-listed equities with positive expected earnings growth.
  • The price/operating cash flow metric for Lemaitre Vascular Inc is higher than 85.88% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of 1,091.05%, Lemaitre Vascular Inc's debt growth rate surpasses 98.21% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Lemaitre Vascular Inc are SSTK, SSD, ATRI, PLPC, and CRTO.
  • LMAT's SEC filings can be seen here. And to visit Lemaitre Vascular Inc's official web site, go to www.lemaitre.com.

LMAT Stock Price Chart Interactive Chart >

Price chart for LMAT

LMAT Price/Volume Stats

Current price $38.88 52-week high $39.40
Prev. close $37.75 52-week low $18.76
Day low $36.86 Volume 167,800
Day high $39.40 Avg. volume 131,781
50-day MA $33.99 Dividend yield 0.98%
200-day MA $29.07 Market Cap 790.90M

LeMaitre Vascular, Inc. (LMAT) Company Bio


LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease. The company was founded in 1983 and is based in Burlington, Massachusetts.

LMAT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$38.88$47.7 26%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Lemaitre Vascular Inc. To summarize, we found that Lemaitre Vascular Inc ranked in the 52th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 27% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for LMAT, they are:

  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 22.78% of the free cash flow producing stocks we're observing.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%24%
1%25%
2%26%
3%28%
4%29%
5%30%

Want more companies with a valuation profile/forecast similar to that of Lemaitre Vascular Inc? See CBPO, SNY, EGRX, AMED, and ACIU.


LMAT Latest News Stream


Event/Time News Detail
Loading, please wait...

LMAT Latest Social Stream


Loading social stream, please wait...

View Full LMAT Social Stream

Latest LMAT News From Around the Web

Below are the latest news stories about Lemaitre Vascular Inc that investors may wish to consider to help them evaluate LMAT as an investment opportunity.

Registration - Sidoti's 2020 Fall Virtual Investor Conference is Open Now

Our Biannual Investor Conference has become a leading forum for small-cap companies to interface with investors specifically interested in the small-cap equities.

Yahoo | July 31, 2020

Registration - Sidoti's 2020 Fall Virtual Investor Conference is Now Open.

Our Biannual Investor Conference has become a leading forum for small-cap companies to interface with investors specifically interested in the small-cap equities.

Yahoo | July 30, 2020

LeMaitre Vascular to Present at Upcoming Investor Conferences

BURLINGTON, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in August. JJ Pellegrino, Chief Financial Officer, is scheduled to present at the virtual Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020, at 8:00 AM EDT.David Roberts, President, is scheduled to participate in the virtual 5th Annual Needham Med Tech & Diagnostics 1×1 Conference on Monday, August 17, 2020.About LeMaitre VascularLeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to ad...

Yahoo | July 29, 2020

LeMaitre Vascular, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

LeMaitre Vascular, Inc. (NASDAQ:LMAT) defied analyst predictions to release its quarterly results, which were ahead of...

Yahoo | July 26, 2020

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q2 2020 Results - Earnings Call Transcript

LeMaitre Vascular, Inc. (LMAT) Q2 2020 Earnings Conference Call July 23, 2020 05:00 PM ET Company Participants Joseph Pellegrino - Chief Financial Officer, Treasurer and Secretary George LeMaitre - Chairman and Chief Executive Officer David Roberts - President Conference Call Participants Cecilia Furlong - Canaccord Genuity Group Inc. Andrew Ranieri...

SA Transcripts on Seeking Alpha | July 24, 2020

Read More 'LMAT' Stories Here

LMAT Price Returns

1-mo 18.76%
3-mo 24.44%
6-mo 44.48%
1-year 9.53%
3-year 15.24%
5-year 150.46%
YTD 9.53%
2019 53.77%
2018 -25.13%
2017 26.58%
2016 48.46%
2015 128.81%

LMAT Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full LMAT Dividend History

Continue Researching LMAT

Here are a few links from around the web to help you further your research on Lemaitre Vascular Inc's stock as an investment opportunity:

Lemaitre Vascular Inc (LMAT) Stock Price | Nasdaq
Lemaitre Vascular Inc (LMAT) Stock Quote, History and News - Yahoo Finance
Lemaitre Vascular Inc (LMAT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9695 seconds.